Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Endocrine 2

Conditions

Neuroendocrine Tumors 5Neuroblastoma 2Medulloblastoma 2Carcinoma, Neuroendocrine 2von Hippel-Lindau Disease 1Tumor Positron-Emission Tomography 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Prostatic Neoplasms 1Parathyroid Neoplasms 1Multiple Endocrine Neoplasia 1Meningioma 1Hypoglycemia 1Hyperparathyroidism 1Hypercalcemia 1Carcinoid Tumor 1Cancer Diagnosis 1

Interventions

Everolimus 7avelumab 3Temozolomide 3Etoposide 3Cisplatin 3Bevacizumab 3pembrolizumab 2gallium Ga 68 dotatate 2azaspirane 2Irinotecan 2veliparib 1tocilizumab 1selinexor 1pralsetinib 1pertuzumab 1pasireotide 1lenvatinib 1irinotecan sucrosofate 1carfilzomib 1berzosertib 1belinostat 1Topotecan 1TLC 388 1Radiotherapy 1Radiosurgery 1Radionuclide Imaging 1Positron-Emission Tomography 1Positron Emission Tomography Computed Tomography 1Podophyllotoxin 1Platinum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Carcinoma, Neuroendocrine × gallium Ga 68 dotatate × Clear all
NCT04069299 2026-03-31

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

H. Lee Moffitt Cancer Center and Research Institute

Completed
30 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT01879657 2025-08-06

68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)

Radio Isotope Therapy of America

Phase NA Completed
169 enrolled
Endocrine

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡